Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 331, Issue 1, Pages 158-167Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2010.09.011
Keywords
Endometrial cancer; Estrogen-metabolizing enzymes; Cytochrome P450 1B1 (CYP1B1); Catechol-O-methyltransferase
Categories
Funding
- Slovenian Research Agency [J3-9448]
Ask authors/readers for more resources
Expression levels of genes encoding phase land phase II estrogen-metabolizing enzymes: CYP1A1, CYP1A2, CYP1B1, CYP3A5, CYP3A7, SULT1A1, SULT1E1, SUL7281, COMT, UG72B7, and GSTP1 were studied by real-time PCR in 38 samples of cancerous and adjacent control endometrium. We found significantly lower levels of CYP1B1 and CYP3A7, higher levels of SULT2B1, UG72B7 and GSTP1, and no differences in expression of COMT, CYP1A1, CYP3A5, SULT1E1 and SULT2A1 in the endometrial cancers. The CYP1B1 and COMT proteins were also examined by Western blotting and immunohistochemical staining, supporting the real-time PCR analysis. Lower levels of CYP1B1 detected in cancerous endometrium suggest its important role in control, precancerous tissue. Additionally, we showed for the first time higher protein levels of soluble COMT in cancerous endometrium, and higher levels of membrane-bound COMT in control, precancerous endometrium. The importance of the changed ratio between soluble and membrane-bound COMT still needs to be evaluated in further studies. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available